Xerostomia (VAS) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Antimicrobial lozenge showed no clear difference in xerostomia compared with placebo; GRADE not reported.
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Xerostomia (severe) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower xerostomia (severe) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Chinese medicine led to lower xerostomia (dichotomous, Shenqi Fanghou recipe) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
1 finding from 1 review
Adverse effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
It is very uncertain whether topical NSAID (ketoprofen chewing gum) changes pain intensity (VAS 0-100 mm) compared with local anaesthetic (benzocaine chewing gum) (very low certainty).
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Time off school or work · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
Vomiting · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to higher vomiting (adverse effect) compared with no treatment/placebo (low certainty).
1 finding from 1 review
Time off school or work · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
Failure to complete orthodontic treatment due to pain · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life and other oral related symptoms (loss of taste, dysphagia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Quality of life or participant satisfaction · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life or participant satisfaction · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine (intravenous) showed no clear difference in overall survival compared with amifostine (subcutaneous); GRADE not reported.
1 finding from 1 review
HR 1.36 [0.89, 2.10]
1 study
GRADE not reported
Allergic adverse events · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine 200 mg/m2 three times weekly showed no clear difference in allergic response (adverse effect) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.
1 finding from 1 review
Asthenia · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in asthenia (adverse effect) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review